
Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update
Description
Illumina Inc (ILMN) - Product Pipeline Analysis, 2024 Update
Summary
Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of molecular diagnostics, translational and consumer genomics, and cancer. The company’s portfolio encompasses sequencing kits and reagents; sequencing tools and systems; microarray kits and reagents; molecular biology reagents; and arrays and reagents. It offers human whole-genome sequencing; microarray services; instrument services, training, and consulting. The company serves pharmaceutical companies, academic institutions, genomic research centers, biotechnology companies and clinical research organizations. The company sells its products through direct sales and distributors in the Americas, Asia-Pacific, Europe, the Middle East, and Africa. Illumina is headquartered in San Diego, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Illumina Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
87 Pages
- Illumina Inc Company Overview
- Illumina Inc Company Snapshot
- Illumina Inc Pipeline Products and Ongoing Clinical Trials Overview
- Illumina Inc – Pipeline Analysis Overview
- Business Description
- Illumina Inc - Key Facts
- Illumina Inc - Major Products and Services
- Illumina Inc Pipeline Products by Development Stage
- Illumina Inc Ongoing Clinical Trials by Trial Status
- Illumina Inc Pipeline Products Overview
- Blood-Based Test - Breast Cancer
- Blood-Based Test - Breast Cancer Product Overview
- Blood-Based Test - Breast Cancer Clinical Trial
- Blood-Based Test - Lung Cancer
- Blood-Based Test - Lung Cancer Product Overview
- Blood-Based Test - Lung Cancer Clinical Trial
- Companion Diagnostic Test - Brain Cancer
- Companion Diagnostic Test - Brain Cancer Product Overview
- Companion Diagnostic Test - Cancer
- Companion Diagnostic Test - Cancer Product Overview
- Companion Diagnostic Test - Colorectal Cancer
- Companion Diagnostic Test - Colorectal Cancer Product Overview
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma
- Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma Product Overview
- Companion Diagnostic Test - Lung Cancer
- Companion Diagnostic Test - Lung Cancer Product Overview
- Companion Diagnostic Test - Melanoma
- Companion Diagnostic Test - Melanoma Product Overview
- Companion Diagnostic Test - Oncology
- Companion Diagnostic Test - Oncology Product Overview
- Companion Diagnostic Test - Prostate Cancer
- Companion Diagnostic Test - Prostate Cancer Product Overview
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection
- Companion Diagnostic Test - Pseudomonas Aeruginosa Infection Product Overview
- Diagnostic Aid For Cancer (DAC) Test
- Diagnostic Aid For Cancer (DAC) Test Product Overview
- Diagnostic Test - Infectious Diseases
- Diagnostic Test - Infectious Diseases Product Overview
- Explify Test - CNS Infections
- Explify Test - CNS Infections Product Overview
- Galleri Test
- Galleri Test Product Overview
- Galleri Test Clinical Trial
- HRD CDx Test
- HRD CDx Test Product Overview
- InfiniumDx CytoSNP-12 Assay
- InfiniumDx CytoSNP-12 Assay Product Overview
- Integrated MiniSeq System
- Integrated MiniSeq System Product Overview
- Lab-On-A-Chip
- Lab-On-A-Chip Product Overview
- Long Read Human Whole Genome Assay
- Long Read Human Whole Genome Assay Product Overview
- LSD-100 Lysosomal Storage Enzyme Analyzer
- LSD-100 Lysosomal Storage Enzyme Analyzer Product Overview
- Minimal Residual Disease Test
- Minimal Residual Disease Test Product Overview
- MRSA Screening Test
- MRSA Screening Test Product Overview
- Multiplexed Diagnostic Device
- Multiplexed Diagnostic Device Product Overview
- Next Generation Galleri
- Next Generation Galleri Product Overview
- NGS Diagnostic System
- NGS Diagnostic System Product Overview
- NGS-Based Transplant Diagnostic Assay
- NGS-Based Transplant Diagnostic Assay Product Overview
- NovaSeq 6000 Dx
- Product Status
- Novaseq Dx
- Novaseq Dx Product Overview
- Point-Of-Care Diagnostic Device - HIV
- Point-Of-Care Diagnostic Device - HIV Product Overview
- Portable Benchtop Analyzer - Viral Load Assay
- Portable Benchtop Analyzer - Viral Load Assay Product Overview
- Prenatal Screening Test
- Prenatal Screening Test Product Overview
- TruSight NIPT
- TruSight NIPT Product Overview
- TruSight Oncology 500 - TP53 CDx Assay
- TruSight Oncology 500 - TP53 CDx Assay Product Overview
- TruSight Oncology 500 HRD
- TruSight Oncology 500 HRD Product Overview
- TruSight Oncology 500 HRD Clinical Trial
- TruSight Tumor 170 CDx - LOXO-101
- TruSight Tumor 170 CDx - LOXO-101 Product Overview
- TruSight Tumor 170 CDx - LOXO-292
- TruSight Tumor 170 CDx - LOXO-292 Product Overview
- Verifi Prenatal Test
- Verifi Prenatal Test Product Overview
- Illumina Inc - Key Competitors
- Illumina Inc - Key Employees
- Illumina Inc - Key Employee Biographies
- Illumina Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Joint Venture
- Recent Developments
- Illumina Inc, Recent Developments
- May 29, 2024: Illumina Drives Genomic Testing as Standard of Care in Oncology Through Collaborative Research Presented at ASCO
- May 09, 2024: CNIO Will Help to Improve Cancer Prevention and Personalized Diagnosis with the Most Powerful ‘Gene Reader’
- Mar 27, 2024: GRAIL Presents New Data on Galleri and Its Methylation Platform at the Annual American Association for Cancer Research (AACR) Meeting
- Mar 25, 2024: Nucleus Genomics launches to bring whole-genome sequencing to the public
- Mar 18, 2024: Grail Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
- Feb 27, 2024: Jenny Zheng Joins Illumina as Senior Vice President and General Manager of Greater China
- Feb 16, 2024: Getlabs to offer GRAIL’s early cancer detection test
- Feb 08, 2024: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2023
- Feb 01, 2024: Curative Insurance Company Adds Grail’s Galleri Test to Member Benefits for Multi-Cancer Early Detection
- Jan 30, 2024: GRAIL Partners With Professional Golfers Steve Stricker and Juli Inkster to Raise Awareness of Multi-Cancer Early Detection at Second Annual Galleri Classic PGA TOUR Champions Tournament
- Appendix
- Methodology
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Illumina Inc Pipeline Products and Ongoing Clinical Trials Overview
- Table 2: Illumina Inc Pipeline Products by Equipment Type
- Table 3: Illumina Inc Pipeline Products by Indication
- Table 4: Illumina Inc, Key Facts
- Table 5: Illumina Inc, Major Products and Services
- Table 6: Illumina Inc Number of Pipeline Products by Development Stage
- Table 7: Illumina Inc Pipeline Products Summary by Development Stage
- Table 8: Illumina Inc Ongoing Clinical Trials by Trial Status
- Table 9: Illumina Inc Ongoing Clinical Trials Summary
- Table 10: Blood-Based Test - Breast Cancer - Product Status
- Table 11: Blood-Based Test - Breast Cancer - Product Description
- Table 12: Blood-Based Test - Breast Cancer - Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection: The STRIVE Study
- Table 13: Blood-Based Test - Lung Cancer - Product Status
- Table 14: Blood-Based Test - Lung Cancer - Product Description
- Table 15: Blood-Based Test - Lung Cancer - The SUMMIT Study: Cancer Screening Study with or Without Low Dose Lung CT to Validate a Multi-cancer Early Detection Test
- Table 16: Companion Diagnostic Test - Brain Cancer - Product Status
- Table 17: Companion Diagnostic Test - Brain Cancer - Product Description
- Table 18: Companion Diagnostic Test - Cancer - Product Status
- Table 19: Companion Diagnostic Test - Cancer - Product Description
- Table 20: Companion Diagnostic Test - Colorectal Cancer - Product Status
- Table 21: Companion Diagnostic Test - Colorectal Cancer - Product Description
- Table 22: Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Status
- Table 23: Companion Diagnostic Test - Head And Neck Squamous Cell Carcinoma - Product Description
- Table 24: Companion Diagnostic Test - Lung Cancer - Product Status
- Table 25: Companion Diagnostic Test - Lung Cancer - Product Description
- Table 26: Companion Diagnostic Test - Melanoma - Product Status
- Table 27: Companion Diagnostic Test - Melanoma - Product Description
- Table 28: Companion Diagnostic Test - Oncology - Product Status
- Table 29: Companion Diagnostic Test - Oncology - Product Description
- Table 30: Companion Diagnostic Test - Prostate Cancer - Product Status
- Table 31: Companion Diagnostic Test - Prostate Cancer - Product Description
- Table 32: Companion Diagnostic Test - Pseudomonas Aeruginosa Infection - Product Status
- Table 33: Companion Diagnostic Test - Pseudomonas Aeruginosa Infection - Product Description
- Table 34: Diagnostic Aid For Cancer (DAC) Test - Product Status
- Table 35: Diagnostic Aid For Cancer (DAC) Test - Product Description
- Table 36: Diagnostic Test - Infectious Diseases - Product Status
- Table 37: Diagnostic Test - Infectious Diseases - Product Description
- Table 38: Explify Test - CNS Infections - Product Status
- Table 39: Explify Test - CNS Infections - Product Description
- Table 40: Galleri Test - Product Status
- Table 41: Galleri Test - Product Description
- Table 42: Galleri Test - A Randomized, Controlled Trial to Assess the Clinical Utility of a Multi-cancer Early Detection (MCED) Test for Population Screening in the United Kingdom (UK) When Added to Standard of Care
- Table 43: Galleri Test - A Study to Evaluate the Galleri Blood Test in the Multi-cancer Early Detection Test
- Table 44: Galleri Test - Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity
- Table 45: Galleri Test - REFLECTION: Real World Evidence for Learnings in Early Cancer Detection, a Clinical Practice Learning Program for Galleri
- Table 46: Galleri Test - The Circulating Cell-free Genome Atlas Study
- Table 47: Galleri Test - The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-cancer Early Detection Test in an Eligible Screening Population
- Table 48: Galleri Test - Unintentional Weight Loss and Cancer: A Prospective Trial of Patient-centered Weight Tracking Combined With GRAIL Galleri Testing to Improve Early Detection
- Table 49: HRD CDx Test - Product Status
- Table 50: HRD CDx Test - Product Description
- Table 51: InfiniumDx CytoSNP-12 Assay - Product Status
- Table 52: InfiniumDx CytoSNP-12 Assay - Product Description
- Table 53: Integrated MiniSeq System - Product Status
- Table 54: Integrated MiniSeq System - Product Description
- Table 55: Lab-On-A-Chip - Product Status
- Table 56: Lab-On-A-Chip - Product Description
- Table 57: Long Read Human Whole Genome Assay - Product Status
- Table 58: Long Read Human Whole Genome Assay - Product Description
- Table 59: LSD-100 Lysosomal Storage Enzyme Analyzer - Product Status
- Table 60: LSD-100 Lysosomal Storage Enzyme Analyzer - Product Description
- Table 61: Minimal Residual Disease Test - Product Status
- Table 62: Minimal Residual Disease Test - Product Description
- Table 63: MRSA Screening Test - Product Status
- Table 64: MRSA Screening Test - Product Description
- Table 65: Multiplexed Diagnostic Device - Product Status
- Table 66: Multiplexed Diagnostic Device - Product Description
- Table 67: Next Generation Galleri - Product Status
- Table 68: Next Generation Galleri - Product Description
- Table 69: NGS Diagnostic System - Product Status
- Table 70: NGS Diagnostic System - Product Description
- Table 71: NGS-Based Transplant Diagnostic Assay - Product Status
- Table 72: NGS-Based Transplant Diagnostic Assay - Product Description
- Table 73: Product Status
- Table 74: NovaSeq 6000 Dx - Product Description
- Table 75: Novaseq Dx - Product Status
- Table 76: Novaseq Dx - Product Description
- Table 77: Point-Of-Care Diagnostic Device - HIV - Product Status
- Table 78: Point-Of-Care Diagnostic Device - HIV - Product Description
- Table 79: Portable Benchtop Analyzer - Viral Load Assay - Product Status
- Table 80: Portable Benchtop Analyzer - Viral Load Assay - Product Description
- Table 81: Prenatal Screening Test - Product Status
- Table 82: Prenatal Screening Test - Product Description
- Table 83: TruSight NIPT - Product Status
- Table 84: TruSight NIPT - Product Description
- Table 85: TruSight Oncology 500 - TP53 CDx Assay - Product Status
- Table 86: TruSight Oncology 500 - TP53 CDx Assay - Product Description
- Table 87: TruSight Oncology 500 HRD - Product Status
- Table 88: TruSight Oncology 500 HRD - Product Description
- Table 89: TruSight Oncology 500 HRD - Molecular Landscape Involved in the Onset of Breast Cancer in Patients With Germline BRCA-1/2 Mutations, During or After Therapy With Platinum-based Agents and/or PARP-inhibitors for Ovarian Cancer
- Table 90: TruSight Tumor 170 CDx - LOXO-101 - Product Status
- Table 91: TruSight Tumor 170 CDx - LOXO-101 - Product Description
- Table 92: TruSight Tumor 170 CDx - LOXO-292 - Product Status
- Table 93: TruSight Tumor 170 CDx - LOXO-292 - Product Description
- Table 94: Verifi Prenatal Test - Product Status
- Table 95: Verifi Prenatal Test - Product Description
- Table 96: Illumina Inc, Key Employees
- Table 97: Illumina Inc, Key Employee Biographies
- Table 98: Illumina Inc, Subsidiaries
- Table 99: Illumina Inc, Joint Venture
- Table 100: Glossary
- List of Figures
- Figure 1: Illumina Inc Pipeline Products by Equipment Type
- Figure 2: Illumina Inc Pipeline Products by Development Stage
- Figure 3: Illumina Inc Ongoing Clinical Trials by Trial Status
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.